Rhomboid Intercostal Sub Serratus Plane Block Versus Serratus Anterior Plane Block in Thoractomy

March 4, 2025 updated by: Yasser S Mostafa, MD

Analgesic Efficacy of Ultrasound-Guided Rhomboid Intercostal Sub Serratus Plane Block Versus Serratus Anterior Plane Block With General Anesthesia in Thoracotomy

The objective of the current study is to compare the efficacy of the analgesic effect of ultrasound-guided unilateral Rhomboid intercostal and sub serratus plane block (RISS) versus Serratus anterior plane block (SAPB) in Thoracotomy incision.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Open thoracotomy is commonly considered to be one of the most agonizing surgical operations. Pain following thoracotomy greatly impedes patient recovery and postoperative respiration. The pain experienced after a thoracotomy can originate from various factors, including the surgical incision, injury to the ribs and intercostal nerves, manipulation of the pleura and lung tissue, and the placement of a drainage tube.Recent advances in regional anesthesia techniques have aimed to provide more targeted and effective pain relief. Among these, ultrasound-guided fascial plane blocks, such as the rhomboid intercostal sub-serratus plane (RISS) block and the serratus anterior plane (SAP) block, have emerged as promising options. Both blocks target the thoracic nerves, but they differ in their anatomical approach and potential analgesic effects Postoperative pain was not only related to a comfortable recovery but also related to postoperative complications including pulmonary dysfunction, so the management of postoperative pain is an important part of the care of post operation.

Regional anesthesia techniques have been shown to have a good effect on postoperative analgesia and helps patients gain early recovery after operation.

Serratus anterior plane block (SAPB) is an easy, and safe method used for blockade of the sensory plane of the lateral cutaneous branch of the intercostal nerve (T2-T9).

The Serratus anterior plane block targets the lateral cutaneous branches of the thoracic intercostal nerves, which arise from the anterior rami of the thoracic spinal nerves and run in a neurovascular bundle immediately inferior to each rib. At the midaxillary line, the lateral cutaneous branches of the thoracic intercostal nerve traverse through the internal intercostal, external intercostal, and serratus anterior muscles innervating the musculature of the lateral thorax. These branches of the intercostal nerves travel through the two potential spaces described above.

The "Rhomboid intercostal and sub serratus plane block" (RISS) is a relatively newer block technique whose efficacy was documented in patients undergoing thoracic surgeries.

The RISS plane block involves the injection of local anesthetics into fascial planes, theoretically allowing for catheter placement to achieve continuous analgesia. Successful RISS plane blocks have been reported in various procedures, including lung transplantation, radical mastectomy, and nephrectomy, strongly suggesting favorable outcomes in postoperative pain relief.

In 2016, Elsharkawy et al. introduced a RA technique known as the rhomboid intercostal block (RIB). Rhomboid intercostal block involves injecting a local anesthetic into the upper intercostal muscle plane beneath the rhomboid muscles, providing analgesia to both the anterior and posterior thorax.Based on past studies, investigators found that RISS and SAPB are effectively decrease total opioid consumption, so investigators hypothesized one of them is the best.

Statistical analysis:

Statistical analysis will be conducted using IBM SPSS Statistics 22(IBM Corp., Armonk, NY, USA). The normal distribution of data will be assessed by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Mean and standard deviation will be used as descriptive statistics for normally distributed numerical variables, while median and interquartile range (25th to 75th percentiles) will be used as descriptive statistics for non-normally distributed numerical variables. In addition, Chi-square test or fisher exact test will be employed to test the significance between categorical variables as appropriate. Independent t test will be employed for numerical data that exhibited normal distribution, whereas the Mann-Whitney test will be used for numerical data that did not adhere to normal distribution. A significance level of p < 0.05 will be deemed to be statistically significant.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Emad El Mohamed Abd El-Razek, M.Sc.
  • Phone Number: +2 0 109 400 6418
  • Email: ema18@fayoum.edu.eg

Study Contact Backup

Study Locations

    • Faiyum Governorate
      • Madīnat al Fayyūm, Faiyum Governorate, Egypt, 63514
        • Recruiting
        • Fayoum University hospital
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Patients aged 18-70 years.
  • Patients scheduled for unilateral Thoracotomy.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Patients who are candidates for general anesthesia.
  • No history of severe allergies to local anesthetics or other medications used during the procedure.

Exclusion Criteria:

  • ASA PS class ≥ IV patients.
  • obese (BMI ≥ 35) patients.
  • Patients with uncontrolled cardiovascular.
  • patients with neurological deficits, cardiopulmonary, hepatorenal , or metabolic diseases; anticoagulants; any drug allergies.
  • Patients with emergency surgeries or re-do surgeries.
  • Systemic infections or infections at the site of injection.
  • Psychiatric illnesses (schizophrenia, bipolar, uncontrolled anxiety or depression).
  • Narcotic dependency.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group R
A high- frequency linear ultrasound transducer will be placed longitudinally (in the sagittal plane) on the patient's back, just 2 cm medial to the medial scapular border. Then, the probe will be slightly rotated to obtain an oblique parasagittal plane. The following landmarks will be identified: the trapezius muscle, rhomboid major muscle, intercostal muscles, pleura, and lungs (from superficial to deep in order of appearance). The rhomboid major muscle will be distinguished at the level of the T6 and T7 vertebrae, below the trapezius muscle.
A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
After the location will be confirmed through hydrodissection of 1 ml on the plane between the rhomboid major and the underlying intercostal muscles after confirming a negative aspiration via a a 22-gauge short bevel sonovisible needle (Spinocan, B. Braun Melsungen AG, Germany) using an in-plane technique then 10 ml of bupivacaine (concentration 0.25%) will be injected. and its spread will be manifested by the hydrodissection and widening of the plane visualized by ultrasound.
Other Names:
  • Marcaine 0.25%
Active Comparator: Group S
  • The patient will be positioned laterally, and routine skin disinfection and draping will be completed.
  • Investigators also will use a linear ultrasound probe (Philips clear vue350, Philips healthcare, Andover MAO1810, USA, Machine ID: 1385, Nile medical center, service@nilemed.net) for performing the block.
  • The fifth rib will be identified along the mid-axillary line to locate the deep serratus anterior muscle and the superficial latissimus dorsi muscle.
  • The needle will be inserted between the fifth and fourth ribs using a 22G (50 mm) puncture needle.
A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
After the location will be confirmed through hydrodissection of 1 ml on the plane between the rhomboid major and the underlying intercostal muscles after confirming a negative aspiration via a a 22-gauge short bevel sonovisible needle (Spinocan, B. Braun Melsungen AG, Germany) using an in-plane technique then 10 ml of bupivacaine (concentration 0.25%) will be injected. and its spread will be manifested by the hydrodissection and widening of the plane visualized by ultrasound.
Other Names:
  • Marcaine 0.25%

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total opioid consumption
Time Frame: 24 hours postoperatively.
in microgram
24 hours postoperatively.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total intraoperative opioid consumption
Time Frame: from begining of operation till 5 minutes after extubation
in microgram
from begining of operation till 5 minutes after extubation
Visual analog pain score at rest
Time Frame: Immediately after the procedures
Ranging from 0 indicating no pain to 10 indicating extreme pain
Immediately after the procedures
Visual analog pain score at cough
Time Frame: Immediately after the procedures
Ranging from 0 indicating no pain to 10 indicating extreme pain
Immediately after the procedures
Visual analog pain score at rest
Time Frame: 1 hour postoperatively.
Ranging from 0 indicating no pain to 10 indicating extreme pain
1 hour postoperatively.
Visual analog pain score at cough
Time Frame: 1 hour postoperatively.
Ranging from 0 indicating no pain to 10 indicating extreme pain
1 hour postoperatively.
Visual analog pain score at rest
Time Frame: 3 hours postoperatively.
Ranging from 0 indicating no pain to 10 indicating extreme pain
3 hours postoperatively.
Visual analog pain score at cough
Time Frame: 3 hours postoperatively.
Ranging from 0 indicating no pain to 10 indicating extreme pain
3 hours postoperatively.
Visual analog pain score at rest
Time Frame: 6 hours postoperatively.
Ranging from 0 indicating no pain to 10 indicating extreme pain
6 hours postoperatively.
Visual analog pain score at cough
Time Frame: 6 hours postoperatively.
Ranging from 0 indicating no pain to 10 indicating extreme pain
6 hours postoperatively.
Visual analog pain score at rest
Time Frame: 12 hours postoperatively.
Ranging from 0 indicating no pain to 10 indicating extreme pain
12 hours postoperatively.
Visual analog pain score at cough
Time Frame: 12 hours postoperatively.
Ranging from 0 indicating no pain to 10 indicating extreme pain
12 hours postoperatively.
Visual analog pain score at rest
Time Frame: 24 hours postoperatively.
Ranging from 0 indicating no pain to 10 indicating extreme pain
24 hours postoperatively.
Visual analog pain score at cough
Time Frame: 24 hours postoperatively.
Ranging from 0 indicating no pain to 10 indicating extreme pain
24 hours postoperatively.
Time of first rescue analgesic
Time Frame: 5 minutes before first analgesic request
in minutes
5 minutes before first analgesic request
Baseline Heart rate
Time Frame: 5 minutes before anesthesia
Beat / minute
5 minutes before anesthesia
Intraoperative Heart rate
Time Frame: every 30 minutes along operation
Beat / minute
every 30 minutes along operation
Baseline mean arterial blood pressure
Time Frame: 5 minutes before anesthesia
mmHg
5 minutes before anesthesia
Intraoperative mean arterial blood pressure
Time Frame: every 30 minutes along operation
mmHg
every 30 minutes along operation
Baseline oxygen saturation
Time Frame: 5 minutes before anesthesia
percentage with pulse oximetry
5 minutes before anesthesia
Intraoperative oxygen saturation
Time Frame: every 30 minutes along operation
percentage with pulse oximetry
every 30 minutes along operation
Total length of stay in hospital
Time Frame: 1-2 days
in days
1-2 days
Patient satisfaction score
Time Frame: 12 hours after end of operation and extubation
5 degree Likeart scale where 1 Extremely satisfied to 5 Extremely not satisfied
12 hours after end of operation and extubation
Incidence of hematoma
Time Frame: 30 minutes after nerve block
Yes or no
30 minutes after nerve block
Incidence of local anesthetic toxicity
Time Frame: 30 minutes after nerve block
Yes or no
30 minutes after nerve block
Incidence of nausea
Time Frame: 24 hours postoperative
Yes or no
24 hours postoperative
Incidence of vomiting
Time Frame: 24 hours postoperative
Yes or no
24 hours postoperative
Ramsay sedation score
Time Frame: 24 hours postoperative

From 1 to 5 (1 Awake; agitated or restless or both - 2 Awake; cooperative, oriented, and tranquil - 3 Awake but responds to commands only - 4 Asleep; brisk response to light glabellar tap or loud auditory stimulus - 5 Asleep; sluggish response to light glabellar tap or loud auditory stimulus)

Asleep; no response to glabellar tap or loud auditory stimulus

24 hours postoperative

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Age
Time Frame: 5 minutes before entering operation department
in years
5 minutes before entering operation department
Sex
Time Frame: 5 minutes before entering operation department
Male of female
5 minutes before entering operation department

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mohamed A Hamed, MD, Fayoum University
  • Study Chair: Mahdy A Abdelhady, MD, Fayoum University
  • Study Director: Mina M Sobhy, MD, Fayoum University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

February 19, 2025

First Submitted That Met QC Criteria

February 28, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 4, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Ultrasound

Subscribe